ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). Background: The addition of docetaxel (Doc) or ...
Health-related quality of life in metastatic hormone sensitive prostate cancer (mHSPC): Insights from a network meta-analysis of treatment options. Efficacy and safety of darolutamide versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results